TABLE 2.
Recommended blood testing for potential fecal donors based on presently published guidance and protocolsa
Characteristic | Consistently recommended | Occasionally recommended | Case-by-case basis | Recently recommended |
---|---|---|---|---|
Bacterial tests | ||||
Treponema pallidum serology (23–26, 34, 52) | • | |||
Helicobacter pylori EIA (25) | • | |||
Viral tests | ||||
Cytomegalovirus serology (23, 25, 52) | • | |||
Epstein Barr virus serology (23, 25, 52) | • | |||
Hepatitis A virus IgM (23–26, 34, 52) | • | |||
Hepatitis B virus surface antigen (23–26, 34, 52) | • | |||
Hepatitis C virus antibody (23–26, 34, 52) | • | |||
HIV Ab/Ag including p24 (23–26, 34, 52) | • | |||
HTLV 1 and 2 antibodies (23, 25, 26, 34, 52) | • | |||
JC virus serology (25) | • | |||
Protozoal tests | ||||
Entamoeba histolytica latex agglutination and dipstick (23, 25, 52) | • | |||
Strongyloides stercoralis serology (23, 25, 34, 52) | • | |||
Schistosoma spp. (25) | • | |||
Other blood tests | ||||
Complete blood count (23, 26, 34) | • | |||
Complete metabolic panel (23, 26) | • | |||
Liver function panel (23, 26, 34) | • | |||
ESR and CRP (23, 26, 52) | • |
Consistently recommended, recommended in >4 guidance/protocols; occasionally recommended, recommended in some but not >4 guidance/protocols; case-by-case basis, case-by-case consideration of screening is suggested; recently recommended, recently recommended in response to reported safety concerns. EIA, enzyme immunoassay; ESR, erythrocyte sedimentation rate; CRP, c-reactive protein.